NAUT$2.36+0.86%
Nautilus Biotechnology, Inc.
Sector: Laboratory Analytical InstrumentsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$299.96M
Float & O/S:
Inst Own:
DilutionScan read 37 of Nautilus Biotechnology, Inc.'s SEC filings and found 2 ATM programs and 2 shelf registrations on file for NAUT. The latest dilution event on file is ATM sales on Sep 30, 2026. Analysis updated Oct 29, 2026.
Signal8 Summary
NAUT
Pre-revenue, burning cash, heavy dilution
- Business
- Weak$0-0.2M revenue, $59M net loss, 14.6-month runway
- Stock risk
- HighMicro-cap, $125M ATM, overhead supply 31.5% of shares
Snapshot
Nautilus is a development-stage proteomics company with essentially no revenue ($0 in FY 2025) and a $59.0 million net loss. It burned $52.0 million in free cash flow last year and holds $84.0 million in cash against $27.8 million in debt.
What's Happening Right Now
- : Nautilus will report third-quarter 2026 results before market open on October 27, 2026.
- : Nautilus filed a prospectus supplement on September 18, 2026 for a new $125 million at-the-market stock sale program through TD Cowen, drawn from its $300 million shelf, which could add roughly 111.6 million new shares (about 88% of shares outstanding) at the assumed $1.12 price; the program replaces a prior ATM agreement under which no shares were ever sold.
- : Registered $300.00M of securities for sale on Form S-3.
- : Andreessen Horowitz-affiliated funds sold roughly 1.4 million more shares between August 31 and September 9, 2026 at prices near $0.90-$1.03, dropping below the 5% ownership threshold and ending their 13D reporting obligations.
- : Nautilus published a Nature Methods study on September 4, 2026 showing its platform quantified 130 tau proteoform groups at single-molecule resolution, a scientific validation milestone for its Early Access program rather than a near-term revenue event.
- : Nautilus reported its first-ever revenue of $0.2 million for Q2 2026 (from grant funding and early access sales), a net loss of $14.5 million, and $129.2 million in cash, while shifting R&D focus toward proteoform assays and delaying its broader Broadscale program.
